venous thromboembolism; atrial fibrillation; coumarin
Item
patients with either venous thromboembolism (vte) or atrial fibrillation (af) requiring coumarin therapy for at least 12 weeks and a target inr in the low intensity range (inr range 2-3 in the united kingdom, sweden, germany, austria and greece and inr 2.5-3.5 in the netherlands)
boolean
C1861172 (UMLS CUI [1])
C0004238 (UMLS CUI [2])
C0010206 (UMLS CUI [3])
age
Item
age ≥ 18 years
boolean
C0001779 (UMLS CUI [1])
compliance behavior
Item
ability to attend scheduled visits
boolean
C1321605 (UMLS CUI [1])
informed consent
Item
signed informed consent
boolean
C0021430 (UMLS CUI [1])
mechanical heart valve
Item
presence of a mechanical heart valve
boolean
C0493527 (UMLS CUI [1])
cognitive impairment
Item
severe cognitive impairment
boolean
C1839000 (UMLS CUI [1])
genotype CYP2 gene VKOR gene
Item
known genotype cyp2c9 or vkorc1 at start of the study
boolean
C0017431 (UMLS CUI [1,1])
C1332829 (UMLS CUI [1,2])
C1428184 (UMLS CUI [1,3])
therapy coumarin
Item
previous or current treatment with any coumarin
boolean
C0087111 (UMLS CUI [1,1])
C0010206 (UMLS CUI [1,2])
pregnancy; lactating
Item
pregnancy or lactation
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Study Subject Participation Status
Item
non-eligible subject
boolean
C2348568 (UMLS CUI [1])